It's Biotech Stocks' Time to Shine
Bets on interest-rate cuts plus a surge in pharma deals mean the worst is likely over for the biotech sector.
Bets on interest-rate cuts plus a surge in pharma deals mean the worst is likely over for the biotech sector.